Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 100

Similar articles for PubMed (Select 23390010)

1.

Cationized ferritin as a magnetic resonance imaging probe to detect microstructural changes in a rat model of non-alcoholic steatohepatitis.

Beeman SC, Mandarino LJ, Georges JF, Bennett KM.

Magn Reson Med. 2013 Dec;70(6):1728-38. doi: 10.1002/mrm.24619.

2.

Looking Beyond the Surface of Adult Moyamoya Disease: Brain Magnetic Resonance Imaging Microstructural Changes and Cognitive Dysfunction.

Hamade YJ, Aoun RJ, Zammar SG, DeMent SE, Patel NP, Bendok BR.

World Neurosurg. 2015 Jul;84(1):18-20. doi: 10.1016/j.wneu.2015.05.001. Epub 2015 May 6. No abstract available.

PMID:
25957727
3.

Successful Treatment of Rapid Onset, Symptomatic de novo Non-alcoholic Steatohepatitis Following Liver Transplantation: A Case Report.

Cuschieri JR, John BK, Miick R, Ortiz JA, Hashemi N.

J Clin Exp Hepatol. 2013 Mar;3(1):70-4. doi: 10.1016/j.jceh.2013.01.001. Epub 2013 Jan 25.

4.

Non-invasive Diagnosis of Fibrosis in Non-alcoholic Fatty Liver Disease.

Arora A, Sharma P.

J Clin Exp Hepatol. 2012 Jun;2(2):145-55. doi: 10.1016/S0973-6883(12)60103-0. Epub 2012 Jul 21.

5.

(-)-Epigallocatechin-3-gallate suppresses hepatic preneoplastic lesions developed in a novel rat model of non-alcoholic steatohepatitis.

Sumi T, Shirakami Y, Shimizu M, Kochi T, Ohno T, Kubota M, Shiraki M, Tsurumi H, Tanaka T, Moriwaki H.

Springerplus. 2013 Dec 27;2:690. doi: 10.1186/2193-1801-2-690. eCollection 2013.

6.

The clinical significance of serum ferritin in pediatric non-alcoholic Fatty liver disease.

Na JH, Park SW, Kang Y, Koh H, Kim S.

Pediatr Gastroenterol Hepatol Nutr. 2014 Dec;17(4):248-56. doi: 10.5223/pghn.2014.17.4.248. Epub 2014 Dec 31.

7.

Ezetimibe for the treatment of nonalcoholic steatohepatitis: assessment by novel magnetic resonance imaging and magnetic resonance elastography in a randomized trial (MOZART trial).

Loomba R, Sirlin CB, Ang B, Bettencourt R, Jain R, Salotti J, Soaft L, Hooker J, Kono Y, Bhatt A, Hernandez L, Nguyen P, Noureddin M, Haufe W, Hooker C, Yin M, Ehman R, Lin GY, Valasek MA, Brenner DA, Richards L; San Diego Integrated NAFLD Research Consortium (SINC).

Hepatology. 2015 Apr;61(4):1239-50. doi: 10.1002/hep.27647. Epub 2015 Feb 27.

8.

Alcoholic and non-alcoholic steatohepatitis.

Neuman MG, French SW, French BA, Seitz HK, Cohen LB, Mueller S, Osna NA, Kharbanda KK, Seth D, Bautista A, Thompson KJ, McKillop IH, Kirpich IA, McClain CJ, Bataller R, Nanau RM, Voiculescu M, Opris M, Shen H, Tillman B, Li J, Liu H, Thomes PG, Ganesan M, Malnick S.

Exp Mol Pathol. 2014 Dec;97(3):492-510. doi: 10.1016/j.yexmp.2014.09.005. Epub 2014 Sep 11. Review.

PMID:
25217800
9.

Relationship of vitamin D with insulin resistance and disease severity in non-alcoholic steatohepatitis.

Bril F, Maximos M, Portillo-Sanchez P, Biernacki D, Lomonaco R, Subbarayan S, Correa M, Lo M, Suman A, Cusi K.

J Hepatol. 2015 Feb;62(2):405-11. doi: 10.1016/j.jhep.2014.08.040. Epub 2014 Sep 6.

PMID:
25195551
11.

Systems level metabolic phenotype of methotrexate administration in the context of non-alcoholic steatohepatitis in the rat.

Kyriakides M, Hardwick RN, Jin Z, Goedken MJ, Holmes E, Cherrington NJ, Coen M.

Toxicol Sci. 2014 Nov;142(1):105-16. doi: 10.1093/toxsci/kfu160. Epub 2014 Aug 21.

12.

A non-invasive prediction model for non-alcoholic steatohepatitis in paediatric patients with non-alcoholic fatty liver disease.

Eng K, Lopez R, Liccardo D, Nobili V, Alkhouri N.

Dig Liver Dis. 2014 Nov;46(11):1008-13. doi: 10.1016/j.dld.2014.07.016. Epub 2014 Aug 6.

PMID:
25106814
13.

The value of liver and spleen ADC measurements in the diagnosis and follow up of hepatic fibrosis in chronic liver disease.

Tokgöz Ö, Unal I, Turgut GG, Yildiz S.

Acta Clin Belg. 2014 Dec;69(6):426-32. doi: 10.1179/2295333714Y.0000000062. Epub 2014 Aug 7.

PMID:
25103596
14.

Non-alcoholic fatty liver disease and type 2 diabetes mellitus: the liver disease of our age?

Firneisz G.

World J Gastroenterol. 2014 Jul 21;20(27):9072-89. doi: 10.3748/wjg.v20.i27.9072. Review.

15.

CEUS and Fibroscan in non-alcoholic fatty liver disease and non-alcoholic steatohepatitis.

Cocciolillo S, Parruti G, Marzio L.

World J Hepatol. 2014 Jul 27;6(7):496-503. doi: 10.4254/wjh.v6.i7.496.

16.

Measurement of liver stiffness as a non-invasive method for diagnosis of non-alcoholic fatty liver disease.

Yoshioka K, Hashimoto S, Kawabe N.

Hepatol Res. 2015 Jan;45(2):142-51. doi: 10.1111/hepr.12388. Epub 2014 Jul 29.

PMID:
25040931
17.

Radiologic evaluation of nonalcoholic fatty liver disease.

Lee SS, Park SH.

World J Gastroenterol. 2014 Jun 21;20(23):7392-402. doi: 10.3748/wjg.v20.i23.7392. Review.

18.

Metabolomics-based search for therapeutic agents for non-alcoholic steatohepatitis.

Terashima Y, Nishiumi S, Minami A, Kawano Y, Hoshi N, Azuma T, Yoshida M.

Arch Biochem Biophys. 2014 Aug;555-556:55-65. doi: 10.1016/j.abb.2014.05.013. Epub 2014 May 22.

PMID:
24857839
19.

Non-invasive fibrosis seromarkers as a predictor of liver fibrosis in chronic hepatitis C and/or non-alcoholic steatohepatitis.

Ahmed L, Salama H, Ahmed R, Hamdy S, Al-Akel W, Shafi SA, Mahgoub A, Hareedy A, Fathy W.

Arab J Gastroenterol. 2009 Mar;10(1):14-20. doi: 10.1016/j.ajg.2009.03.007. Epub 2009 May 3.

PMID:
24842131
20.

Pediatric non-alcoholic steatohepatitis: the first report on the ultrastructure of hepatocyte mitochondria.

Lotowska JM, Sobaniec-Lotowska ME, Bockowska SB, Lebensztejn DM.

World J Gastroenterol. 2014 Apr 21;20(15):4335-40. doi: 10.3748/wjg.v20.i15.4335.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk